-transparent.png){kind=logo}
The effect of a new alpha-glucosidase inhibitor (BAY m 1099), a 1-deoxynojirimycin derivative, was studied in 10 black patients with Type II diabetes mellitus. It produced significant lowering of blood glucose concentration after standardized maize porridge meals. No significant untoward effects were noted. BAY m 1099 appears to offer potential benefit in the management of Type II diabetics, and more extensive clinical investigation is warranted.
Related Publications
P H Joubert, and
W J Bam, and
N Manyane
January 1989,
European journal of clinical pharmacology,
P H Joubert, and
W J Bam, and
N Manyane
November 1986,
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
P H Joubert, and
W J Bam, and
N Manyane
January 1986,
European journal of clinical pharmacology,
P H Joubert, and
W J Bam, and
N Manyane
November 1979,
Diabetologia,
P H Joubert, and
W J Bam, and
N Manyane
October 1987,
Clinical pharmacology and therapeutics,
P H Joubert, and
W J Bam, and
N Manyane
April 1986,
Klinische Wochenschrift,
P H Joubert, and
W J Bam, and
N Manyane
June 1994,
The Netherlands journal of medicine,
P H Joubert, and
W J Bam, and
N Manyane
January 1998,
Bioscience, biotechnology, and biochemistry,
P H Joubert, and
W J Bam, and
N Manyane
January 1994,
Bioscience, biotechnology, and biochemistry,
P H Joubert, and
W J Bam, and
N Manyane
August 1989,
Biochemical pharmacology,
